206 related articles for article (PubMed ID: 27701763)
1. Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.
Swarts DR; Rudelius M; Claessen SM; Cleutjens JP; Seidl S; Volante M; Ramaekers FC; Speel EJ
Histopathology; 2017 Feb; 70(3):412-422. PubMed ID: 27701763
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.
Clay V; Papaxoinis G; Sanderson B; Valle JW; Howell M; Lamarca A; Krysiak P; Bishop P; Nonaka D; Mansoor W
Clin Transl Oncol; 2017 May; 19(5):579-586. PubMed ID: 27848218
[TBL] [Abstract][Full Text] [Related]
3. Interobserver variability for the WHO classification of pulmonary carcinoids.
Swarts DR; van Suylen RJ; den Bakker MA; van Oosterhout MF; Thunnissen FB; Volante M; Dingemans AM; Scheltinga MR; Bootsma GP; Pouwels HM; van den Borne BE; Ramaekers FC; Speel EJ
Am J Surg Pathol; 2014 Oct; 38(10):1429-36. PubMed ID: 25046341
[TBL] [Abstract][Full Text] [Related]
4. Distinctive pathological and clinical features of lung carcinoids with high proliferation index.
Marchiò C; Gatti G; Massa F; Bertero L; Filosso P; Pelosi G; Cassoni P; Volante M; Papotti M
Virchows Arch; 2017 Dec; 471(6):713-720. PubMed ID: 28631159
[TBL] [Abstract][Full Text] [Related]
5. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.
Walts AE; Ines D; Marchevsky AM
Mod Pathol; 2012 Sep; 25(9):1258-64. PubMed ID: 22575865
[TBL] [Abstract][Full Text] [Related]
6. The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.
Marchevsky AM; Hendifar A; Walts AE
Mod Pathol; 2018 Oct; 31(10):1523-1531. PubMed ID: 29802361
[TBL] [Abstract][Full Text] [Related]
7. The Role of Histologic Grading and Ki-67 Index in Predicting Outcomes in Pulmonary Carcinoid Tumors.
Dermawan JKT; Farver CF
Am J Surg Pathol; 2020 Feb; 44(2):224-231. PubMed ID: 31490236
[TBL] [Abstract][Full Text] [Related]
8. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids.
Warth A; Fink L; Fisseler-Eckhoff A; Jonigk D; Keller M; Ott G; Rieker RJ; Sinn P; Söder S; Soltermann A; Willenbrock K; Weichert W;
Virchows Arch; 2013 May; 462(5):507-13. PubMed ID: 23559305
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor.
Vesterinen T; Mononen S; Salmenkivi K; Mustonen H; Räsänen J; Salo JA; Ilonen I; Knuuttila A; Haglund C; Arola J
Acta Oncol; 2018 Aug; 57(8):1109-1116. PubMed ID: 29463166
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Immunohistochemistry for Ki-67 and OTP on Small Biopsies of Pulmonary Carcinoid Tumors: Ki-67 Index Predicts Progression-free Survival and Atypical Histology.
Naso JR; Jenkins SM; Roden AC; Yi ES; Lo YC; Bois MC; Maleszewski JJ; Aubry MC; Boland JM
Am J Surg Pathol; 2024 Jun; 48(6):742-750. PubMed ID: 38584496
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cyclin A2 and B1 expression in lung carcinoids.
Brcic L; Heidinger M; Sever AZ; Zacharias M; Jakopovic M; Fediuk M; Maier A; Quehenberger F; Seiwerth S; Popper H
Pathology; 2019 Aug; 51(5):481-486. PubMed ID: 31230818
[TBL] [Abstract][Full Text] [Related]
12. Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors.
Wang HY; Li ZW; Sun W; Yang X; Zhou LX; Huang XZ; Jia L; Lin DM
Chin Med J (Engl); 2019 Mar; 132(5):551-561. PubMed ID: 30807354
[TBL] [Abstract][Full Text] [Related]
13. [Pulmonary carcinoid: analysis of a single institutional experience and prognostic factors].
Correia Sda S; Pinto C; Bernardo J
Acta Med Port; 2014; 27(6):749-54. PubMed ID: 25641291
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic imaging of typical lung carcinoids: relationship between MDCT,
Danti G; Berti V; Abenavoli E; Briganti V; Linguanti F; Mungai F; Pradella S; Miele V
Radiol Med; 2020 Aug; 125(8):715-729. PubMed ID: 32189174
[TBL] [Abstract][Full Text] [Related]
15. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
16. Grading the neuroendocrine tumors of the lung: an evidence-based proposal.
Rindi G; Klersy C; Inzani F; Fellegara G; Ampollini L; Ardizzoni A; Campanini N; Carbognani P; De Pas TM; Galetta D; Granone PL; Righi L; Rusca M; Spaggiari L; Tiseo M; Viale G; Volante M; Papotti M; Pelosi G
Endocr Relat Cancer; 2014 Feb; 21(1):1-16. PubMed ID: 24344249
[TBL] [Abstract][Full Text] [Related]
17. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity.
Laitinen KL; Soini Y; Mattila J; Pääkkö P
Cancer; 2000 Apr; 88(7):1590-8. PubMed ID: 10738217
[TBL] [Abstract][Full Text] [Related]
18. Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumours of the Lung.
Garg R; Bal A; DAS A; Singh N; Singh H
Turk Patoloji Derg; 2019; 35(1):15-21. PubMed ID: 30070306
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied.
Fabbri A; Cossa M; Sonzogni A; Papotti M; Righi L; Gatti G; Maisonneuve P; Valeri B; Pastorino U; Pelosi G
Virchows Arch; 2017 Feb; 470(2):153-164. PubMed ID: 28054150
[TBL] [Abstract][Full Text] [Related]
20. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
